| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Sage Therapeutics Inc (NASDAQ: SAGE)
SAGE Technical Analysis
5
| As on 9th Jun 2023 SAGE STOCK Price closed @ 59.54 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 36.96 & Strong Buy for SHORT-TERM with Stoploss of 39.66 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SAGESTOCK Price
| Open | 57.03 | Change | Price | % |
| High | 59.68 | 1 Day | 2.84 | 5.01 |
| Low | 56.46 | 1 Week | 10.04 | 20.28 |
| Close | 59.54 | 1 Month | 12.14 | 25.61 |
| Volume | 1000000 | 1 Year | 18.44 | 44.87 |
| 52 Week High 56.53 | 52 Week Low 27.52 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| SAGE Daily Charts |
SAGE Intraday Charts |
Whats New @ Bazaartrend |
SAGE Free Analysis |
|
|
SAGE Important Levels Intraday
| RESISTANCE | 65.74 |
| RESISTANCE | 63.75 |
| RESISTANCE | 62.52 |
| RESISTANCE | 61.29 |
| SUPPORT | 57.79 |
| SUPPORT | 56.56 |
| SUPPORT | 55.33 |
| SUPPORT | 53.34 |
SAGE Forecast May 2024
| 4th UP Forecast | 83.18 |
| 3rd UP Forecast | 75.6 |
| 2nd UP Forecast | 70.91 |
| 1st UP Forecast | 66.23 |
| 1st DOWN Forecast | 52.85 |
| 2nd DOWN Forecast | 48.17 |
| 3rd DOWN Forecast | 43.48 |
| 4th DOWN Forecast | 35.9 |
SAGE Weekly Forecast
| 4th UP Forecast | 66.13 |
| 3rd UP Forecast | 64.02 |
| 2nd UP Forecast | 62.71 |
| 1st UP Forecast | 61.40 |
| 1st DOWN Forecast | 57.68 |
| 2nd DOWN Forecast | 56.37 |
| 3rd DOWN Forecast | 55.06 |
| 4th DOWN Forecast | 52.95 |
SAGE Forecast2024
| 4th UP Forecast | 121.82 |
| 3rd UP Forecast | 101.85 |
| 2nd UP Forecast | 89.5 |
| 1st UP Forecast | 77.15 |
| 1st DOWN Forecast | 41.93 |
| 2nd DOWN Forecast | 29.58 |
| 3rd DOWN Forecast | 17.23 |
| 4th DOWN Forecast | -2.74 |
Sage Therapeutics Inc ( NASDAQ USA Symbol : SAGE )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SAGE Business Profile
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Address: 215 First Street, Cambridge, MA, United States, 02142
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service